Home » Stocks » CERS

Cerus Corporation (CERS)

Stock Price: $5.91 USD -0.34 (-5.44%)
Updated November 24, 2:59 PM EST - Market open

Stock Price Chart

Key Info

Market Cap 987.81M
Revenue (ttm) 107.15M
Net Income (ttm) -62.40M
Shares Out 167.14M
EPS (ttm) -0.40
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day November 24
Last Price $5.91
Previous Close $6.25
Change ($) -0.34
Change (%) -5.44%
Day's Open 6.27
Day's Range 5.90 - 6.31
Day's Volume 982,156
52-Week Range 2.71 - 7.94

More Stats

Market Cap 987.81M
Enterprise Value 913.81M
Earnings Date (est) Mar 9, 2021
Ex-Dividend Date n/a
Shares Outstanding 167.14M
Float 163.34M
EPS (basic) -0.39
EPS (diluted) -0.40
FCF / Share -0.26
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 10.49M
Short Ratio 7.59
Short % of Float 6.42%
Beta 1.24
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio 9.22
PB Ratio 9.53
Revenue 107.15M
Operating Income -60.40M
Net Income -62.40M
Free Cash Flow -42.47M
Net Cash 74.00M
Net Cash / Share 0.44
Gross Margin 48.71%
Operating Margin -56.37%
Profit Margin -58.20%
FCF Margin -39.64%
ROA -19.98%
ROE -73.39%
ROIC -31.80%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Forecasts

Analyst Ratings (5)

Buy 5
Overweight 0
Hold 0
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

$9.10*
(53.98% upside)
Low
8.00
Current: $5.91
High
10.00
Target: 9.10
*Average 12-month price target from 5 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Year2019201820172016201520142013201220112010
Revenue93.7776.0551.3339.2834.2236.4239.6636.7030.6021.68
Revenue Growth23.3%48.17%30.68%14.76%-6.02%-8.17%8.07%19.91%41.17%-
Gross Profit60.3644.4228.8018.9810.7615.2317.0616.0812.079.63
Operating Income-66.23-54.99-57.53-61.45-61.08-44.50-28.30-17.39-18.37-17.39
Net Income-71.24-57.56-60.59-62.91-55.87-38.76-43.34-15.92-16.98-16.91
Shares Outstanding14013210810296.0774.7767.5754.5248.0540.30
Earnings Per Share-0.51-0.44-0.56-0.62-0.61-0.61-0.64-0.33-0.35-0.42
Operating Cash Flow-65.84-31.25-52.24-53.53-51.13-39.81-26.66-13.92-15.63-14.27
Capital Expenditures-8.94-1.14-0.35-0.56-0.72-2.08-0.66-0.08-0.16-1.69
Free Cash Flow-74.77-32.39-52.59-54.09-51.85-41.89-27.33-14.00-15.79-15.96
Cash & Equivalents88.1512060.9471.8110851.8057.9827.0026.0930.31
Total Debt64.4529.8729.8019.3819.809.873.377.727.224.89
Net Cash / Debt23.7090.4431.1552.4488.6941.9354.6219.2818.8725.42
Assets16616398.2410313981.7883.3848.9245.3748.17
Liabilities10878.9459.3045.6944.6440.2640.5929.8127.0524.44
Book Value57.0584.5238.9457.7994.7741.5242.8019.1118.3123.73
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Cerus Corporation
Country United States
Employees 254
CEO William Mariner Greenman

Stock Information

Ticker Symbol CERS
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: CERS
IPO Date January 30, 1997

Description

Cerus Corporation, a biomedical products company, focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System, a proprietary technology for controlling biological replication is designed to reduce blood-borne pathogens in donated blood components intended for transfusion. The company offers INTERCEPT Blood Systems for platelets and plasma that is designed to inactivate blood-borne pathogens in platelets and plasma donated for transfusion; and INTERCEPT Blood System for red blood cells to inactivate blood-borne pathogens in red blood cells donated for transfusion. It sells platelet and plasma systems through its direct sales force and distributors in the United States, Europe, the Commonwealth of Independent States, the Middle East, Latin America, and internationally. The company has a collaboration with the National Trauma Institute to supply Intercept plasma for use in the plasma resuscitation without lung injury (PROpOLIs) clinical study. Cerus Corporation was founded in 1991 and is headquartered in Concord, California.